Theravance Biopharma (TBPH) Misses Q1 EPS by 9c

Theravance Biopharma (NASDAQ: TBPH) reported Q1 EPS of ($0.35), $0.09 worse than the analyst estimate of ($0.26). Revenue for the quarter came in at $10.4 million versus the consensus estimate of $13.98 million.

For earnings history and earnings-related data on Theravance Biopharma (TBPH) click here.

You May Also Be Interested In

• Citrini flags overheating concerns as leverage, chip rally weigh on KOSPI
• Ares Management, L.P. (ARES) PT Raised to $153 at TD Cowen
• Goldman "broadly" raises estimates for LTL and truckload stocks